Supplementary Figures 1 - 9 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development

PDF file - 1579K, Supplementary Figure 1: Histopathological similarity between tumor lines and matched patient tumors. Supplementary Figure 2: Growth curves, host plasma PSA levels and response to castration/Bicalutmide in the tumor lines. Supplementary Figure 3: Similarity of genome copy number between tumor lines and matched patient tumors. Supplementary Figure 4: Conservation of genome copy number after multiple generations of serial passaging. Supplementary Figure 5: Molecular characteristics of transplantable tumour lines. Supplementary Figure 6: Androgen withdrawal leads to the development of castrate-resistant lines. Supplementary Figure 7: Characterization of the neuroendocrine prostate cancer phenotype in LTL331R. Supplementary Figure 8: Evidence of adaptive response to castration in LTL331. Supplementary Figure 9: Genes potentially predisposing LTL331 to neuroendocrine transdifferentiation represent candidate molecular markers for risk stratification.